FIRST U.S. AND INTERNATIONAL SURGICAL IMPLANTATIONS OF ZIP 51™ MIS INTERSPINOUS IMPLANT PERFORMED
CARLSBAD, Calif., April 28, 2015 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (TSXV:ASG) announced today the first surgical implantations of the company's ZIP 51™ Minimally Invasive Interspinous Implant in the United States and Germany.
The U.S. surgery was performed at NEA Baptist Memorial Hospital in Jonesboro, Arkansas by Dr. Rebecca Barrett-Tuck. The international surgery was performed at the Protestant Hospital in Göttingen, Germany by Dr. Christian Reparon.
"The ZIP 51 MIS interspinous fusion system is a great option for the L5-S1 segment," said Dr. Reparon. The instrumentation is very intuitive, easy to use and the implantation is fast and simple via a small incision."
"Aurora Spine's ZIP 51™ implant, the newest addition to the ZIP™ product line, was developed to deliver rigid stabilization with bone graft at the L5-S1 level of the human spine," said Laszlo Garamszegi, Aurora Spine's CTO. "Aurora Spine is pleased to offer the ZIP 51 implant as a distinctive sacral fusion option to surgeons and patients worldwide as part of the Aurora Spine Screwless Procedure™."
"We are very excited to offer our ZIP 51 device internationally," said Sven Claes, International Product Director of Aurora Spine. "The implant features flared lower spikes which are designed to increase the possibility of greater bone purchase. Like our ZIP ULTRA™ implant, the ZIP 51 MIS interspinous fixation implant for spinal fusion, consists of the ZIP ONE-STEP™ Locking Mechanism, and various sizes to accommodate variations in patient anatomy which eliminates the use of a set screw."
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
For more information, please contact:
Aurora Spine Corporation
President and Chief Executive Officer
Chief Financial Officer